Perspective Therapeutics (CATX) News

NYSE: CATXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.66-0.05 (-1.85%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

CATX news summary

We found 1 recent headline mentioning Perspective Therapeutics (CATX): 1 in the past week and 1 in the past 30 days, most often from GlobeNewswire. For price context, CATX is down 1.85% at $2.66. The most recent story, "Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors", was published by GlobeNewswire on Oct 8, 2026.

Headlines link to the original publishers. MetaCap does not republish third-party articles.

Summary generated from market data by MetaCap's automated system. Methodology

Latest Perspective Therapeutics headlines

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous TumorsSEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…GlobeNewswire2d ago